Stefania Spila Alegiani
Overview
Explore the profile of Stefania Spila Alegiani including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
430
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Da Cas R, Spila Alegiani S, Mayer F, Cutillo M, Morciano C, Annunziata A, et al.
Recenti Prog Med
. 2024 Dec;
115(12):614-615.
PMID: 39688049
Aim of the study was to assess the use of pharmacological therapies provided in Nursing Homes and Protected Residences of the Umbria Region, with reference to central nervous system medications....
2.
Lopes S, Servadio M, Spini A, LAbbate L, Ingrasciotta Y, Giometto S, et al.
Expert Opin Biol Ther
. 2024 Dec;
25(1):119-131.
PMID: 39668420
Background: Monitoring biologic drug therapy during pregnancy in women with immune-mediated inflammatory diseases (IMIDs) is crucial to ensure treatments align with evidence-based practices. Research Design And Methods: A retrospective cohort...
3.
Bellini A, Finocchietti M, Rosa A, Masiero L, Trapani S, Cardillo M, et al.
BMJ Open
. 2024 Nov;
14(11):e087373.
PMID: 39532354
Objectives: To investigate the use of maintenance immunosuppressive treatments following liver transplantation and to compare their risk-benefit profiles in clinical practice. Design: Retrospective multicentrer cohort study. Setting: Four Italian regions...
4.
Urru S, Mayer F, Spila Alegiani S, Paoloni F, Guella A, Murru R, et al.
Cancers (Basel)
. 2024 Oct;
16(19).
PMID: 39410038
The clinical safety and efficacy of rituximab biosimilars compared to the reference rituximab (Mabthera) have been well established in randomized trials. However, concerns persist regarding the safety of changing from...
5.
Morciano C, Massari M, Cutillo M, Belleudi V, Trifiro G, Mores N, et al.
Drug Saf
. 2024 Jul;
47(11):1157-1169.
PMID: 39068268
Background And Objective: Cases of appendicitis were identified in the pivotal randomized clinical trial on BNT162b2 mRNA vaccine and reported from coronavirus disease 2019 (COVID-19) vaccine pharmacovigilance systems. Three cohort...
6.
Bellini A, Rosa A, Spila Alegiani S, Massari M, Masiero L, Finocchietti M, et al.
Recenti Prog Med
. 2024 Jul;
115(7):341-349.
PMID: 39011916
The post-organ transplant immunosuppressive therapy includes the administration of tacrolimus (Tac) or cyclosporine (CsA), along with antimetabolites (Antim) or mTOR inhibitors, with or without prednisone. A survey was conducted to...
7.
Marino M, Rosa A, Finocchietti M, Bellini A, Poggi F, Massari M, et al.
Front Transplant
. 2024 Jul;
1:1060621.
PMID: 38994384
Background: In immunosuppression after transplantation, several multi-drug approaches are used, involving calcineurin inhibitors (), antimetabolites (), mammalian target of rapamycin inhibitors (), and corticosteroids. However, data on immunosuppressive therapy by...
8.
Mateo-Urdiales A, Fabiani M, Mayer F, Sacco C, Belleudi V, Da Cas R, et al.
BMC Public Health
. 2024 Jun;
24(1):1569.
PMID: 38862939
Background: As of 2024, vaccination remains the main mitigation measure against COVID-19, but there are contradictory results on whether people living with HIV (PLWH) are less protected by vaccines than...
9.
Spini A, Pellegrini G, Ingrasciotta Y, LAbbate L, Bellitto C, Carollo M, et al.
Expert Opin Biol Ther
. 2024 May;
24(5):399-409.
PMID: 38767132
Background: Switch patterns among different biologics and from originators to biosimilars (and vice versa) can be complex in patients with psoriasis (PsO) and psoriatic arthritis (PsA). Objective: The aim of...
10.
Morciano C, Spila Alegiani S, Ippolito F, Belleudi V, Trifiro G, Zanoni G, et al.
PLoS One
. 2024 Jan;
19(1):e0290879.
PMID: 38241309
Background: Recently published studies have reported association of COVID-19 vaccine ChAdOx1-S (Vaxzevria) with Guillain Barré Syndrome (GBS). Less is known about the safety of other COVID-19 vaccines with respect to...